<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>25194977</identifier>
<setSpec>1578-8989</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Aguilera, Paula</dc:author>
<dc:author>Herrero, Carmen</dc:author>
<dc:author>To-Figueras, Jordi</dc:author>
<dc:author>Badenas, Celia</dc:author>
<dc:description xml:lang="en">BACKGROUND AND OBJECTIVES Acute intermittent porphyria (AIP) is a rare disease that results from a deficiency of porphobilinogen deaminase, the third enzyme of the heme biosynthetic pathway. AIP carriers are at risk of presenting acute neurovisceral attacks associated with overproduction of heme-precursors in the liver. PATIENTS AND METHOD We report the characteristics of all AIP patients attended in the Hospital Clinic of Barcelona during the years 1993-2013 and their long-term follow-up. RESULTS Thirty-five AIP patients (33 women, 2 men) experienced acute attacks. Treatment with hemin resolved the acute neurovisceral crisis in all cases. Nine patients presented peripheral neuropathy and persistent sequelae. Long-term follow-up allowed classifying the patients into groups: A, patients with acute symptoms during 1-2 years and subsequent long-lasting clinical remission (n=24) or a few sporadic crises (n=3), and B, patients with recurrent attacks requiring chronic administration of hemin (n=8). In a majority of the patients of group A, the urinary excretion of heme-precursors decreased gradually over time. However, the chronic hemin regime did not induce a decline of urinary heme-precursors in the patients of group B. Additionally, we identified 44 asymptomatic AIP carriers, most (70.5%) with normal values of heme-precursors in urine. CONCLUSIONS A majority of the AIP patients of our series achieved a long-lasting clinical remission. A minority (23%) presented recurrent attacks that required chronic hemin infusions without feasible interruption and without long-term biochemical remission. The type of mutation within the porphobilinogen deaminase gene and also life-style related factors may determine remission time-course.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:subject>Neurovisceral crisis</dc:subject>
<dc:subject>Hemin</dc:subject>
<dc:subject>Hemina</dc:subject>
<dc:subject>Acute intermittent porphyria</dc:subject>
<dc:subject>Crisis neurovisceral</dc:subject>
<dc:subject>Porfiria aguda intermitente</dc:subject>
<dc:subject>Porfobilinógeno deaminasa</dc:subject>
<dc:subject>Porphobilinogen deaminase</dc:subject>
<dc:date>2015 Oct 21 </dc:date>
<dc:title xml:lang="es">Porfiria aguda intermitente: seguimiento a largo término de 35 pacientes.</dc:title>
<dc:title xml:lang="en">[Acute intermittent porphyria: Long-term follow up of 35 patients].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
